R&D Focus on Safety Mechanisms, Existing Product Improvements and Catheter Applications
First written in FY2016. 26 of 34 entries say "Restated". Latest entry: FY2026.
7 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「Accordingly, responsibilities for R&D in basic and applied technologies ranging from information gathering to commercialization are divided among the teams, with activities carried out by 7 departments and 43 staff members. …As a result of these efforts, R&D expenses for the fiscal year were ¥299.345 million, equivalent to 1.3% of net sales.」
The R&D organization comprised 7 departments and 43 staff members, and the company recorded R&D expenses of ¥299.345 million. Development projects for safety-mechanism-equipped needles, catheter products, and overseas regulatory compliance are also becoming more concrete. - FY2026-H1RestatedAnnual report
「Group-wide R&D spending for the six-month interim period was ¥140.919 million. There were no material changes in the status of the Group's R&D activities during the six-month interim period.」
The company recorded R&D expenses of ¥140.919 million for the interim period and stated that there were no material changes in the status of its R&D activities. - FY2025AdvancedAnnual report
「Responsibilities for R&D in basic and applied technologies ranging from information gathering to commercialization are divided among the teams, with activities carried out by 7 departments and 41 staff members. …R&D expenses for the fiscal year were ¥271.548 million, equivalent to 1.2% of net sales.」
The R&D organization changed from 6 departments and 46 staff members to 7 departments and 41 staff members, and the company recorded R&D expenses of ¥271.548 million. The disclosure describes specific development stages, including completion of Chinese registration for Supercath NEO, verification toward a US FDA filing for Supercath 7, and regulatory filing for an ultra-thin sheath. - FY2025-H1RestatedAnnual report
「Group-wide R&D spending for the six-month interim period was ¥130.454 million. There were no material changes in the status of the Group's R&D activities during the six-month interim period.」
The company recorded R&D expenses of ¥130.454 million for the interim period and stated that there were no material changes in the status of its R&D activities. - FY2024-Q3RestatedAnnual report
「Group-wide R&D spending for the nine months ended the third quarter was ¥215.038 million. There were no material changes in the status of the Group's R&D activities during the nine months ended the third quarter.」
The company recorded R&D expenses of ¥215.038 million for the nine months ended the third quarter and stated that there were no material changes in the status of its R&D activities. - FY2024-Q2RestatedAnnual report
「Group-wide R&D spending for the six months ended the second quarter was ¥146.155 million. There were no material changes in the status of the Group's R&D activities during the six months ended the second quarter.」
The company recorded R&D expenses of ¥146.155 million for the six months ended the second quarter and stated that there were no material changes in the status of its R&D activities. - FY2024-Q1RestatedAnnual report
「Group-wide R&D spending for the three months ended the first quarter was ¥64.527 million. There were no material changes in the status of the Group's R&D activities during the three months ended the first quarter.」
The company recorded R&D expenses of ¥64.527 million for the three months ended the first quarter and stated that there were no material changes in the status of its R&D activities. - FY2023AdvancedAnnual report
「Accordingly, responsibilities for R&D in basic and applied technologies ranging from information gathering to commercialization are divided among the teams, with activities carried out by 6 departments and 46 staff members. The activities comprise ① gathering information on customer needs, ② improving existing products, ③ proposals from medical institutions concerning safety measures implemented in clinical settings, ④ proposals from medical institutions concerning contributions to patients' QOL (Quality of Life), and ⑤ the development of catheter technology applications. …As a result of these efforts, R&D expenses for the fiscal year were ¥323.092 million, equivalent to 1.5% of net sales. …Development of examination needles with high cutting performance has progressed, and design verification work is largely complete. …Development of an intermediate catheter for use as a device in endovascular treatment of cerebrovascular conditions has begun.」
The R&D organization expanded from 5 departments and 43 staff members in the previous fiscal year to 6 departments and 46 staff members, while R&D expenses changed from ¥327.960 million to ¥323.092 million. The disclosure describes progress at specific development stages, including near-completion of design verification for examination needles and the start of intermediate-catheter development. - FY2023-Q2RestatedAnnual report
「Group-wide R&D spending for the six months ended the second quarter was ¥111.803 million. There were no material changes in the status of the Group's R&D activities during the six months ended the second quarter.」
The company recorded R&D expenses of ¥111.803 million for the six months ended the second quarter and stated that there were no material changes in the status of its R&D activities. - FY2023-Q1RestatedAnnual report
「Group-wide R&D spending for the three months ended the first quarter was ¥55.451 million. There were no material changes in the status of the Group's R&D activities during the three months ended the first quarter.」
The company recorded R&D expenses of ¥55.451 million for the three months ended the first quarter and stated that there were no material changes in the status of its R&D activities. - FY2022Increase in R&D personnel and decrease in expenses, with development projects becoming more concreteAnnual report
「Accordingly, responsibilities for R&D in basic and applied technologies ranging from information gathering to commercialization are divided among the teams, with activities carried out by 5 departments and 43 staff members. The activities comprise ① gathering information on customer needs, ② improving existing products, ③ proposals from medical institutions concerning safety measures implemented in clinical settings, ④ proposals from medical institutions concerning contributions to patients' QOL (Quality of Life), and ⑤ the development of catheter technology applications. …R&D expenses for the fiscal year were ¥327.960 million, equivalent to 1.6% of net sales.」
R&D staff increased from 40 in the previous fiscal year to 43, while R&D expenses decreased from ¥357.984 million to ¥327.960 million. Development projects for new and improved products are becoming more concrete while the 5 areas are maintained, so this is recorded as a change in the organization and expenses rather than simply as progress. - FY2022-Q3RestatedAnnual report
「Group-wide R&D spending for the nine months ended the third quarter was ¥258.387 million. There were no material changes in the status of the Group's R&D activities during the nine months ended the third quarter.」
The company recorded R&D expenses of ¥258.387 million for the nine months ended the third quarter and stated that there were no material changes in the status of its R&D activities. - FY2022-Q2RestatedAnnual report
「Group-wide R&D spending for the six months ended the second quarter was ¥172.046 million. There were no material changes in the status of the Group's R&D activities during the six months ended the second quarter.」
The company recorded R&D expenses of ¥172.046 million for the six months ended the second quarter and stated that there were no material changes in the status of its R&D activities. - FY2022-Q1RestatedAnnual report
「Group-wide R&D spending for the three months ended the first quarter was ¥79.514 million. There were no material changes in the status of the Group's R&D activities during the three months ended the first quarter.」
The company recorded R&D expenses of ¥79.514 million for the three months ended the first quarter and stated that there were no material changes in the status of its R&D activities. - FY2021AdvancedAnnual report
「Accordingly, responsibilities for R&D ranging from information gathering and basic research to applied research and commercialization are divided among the teams, with activities carried out by 5 departments and 40 staff members. The activities comprise ① gathering information on customer needs, ② improving existing products, ③ proposals from medical institutions concerning safety measures implemented in clinical settings, ④ proposals from medical institutions concerning contributions to patients' QOL (Quality of Life), and ⑤ the development of catheter technology applications. Particular emphasis is placed on the R&D of needle products equipped with mechanisms to prevent needlestick injuries, based on proposals from medical institutions concerning safety measures implemented in clinical settings, and catheter products for intravascular treatment related to intervention and IVR. As a result of these efforts, R&D expenses for the fiscal year were ¥357.984 million, equivalent to 1.9% of net sales.」
R&D staff increased from 38 to 40, while R&D expenses increased from ¥218.544 million to ¥357.984 million. Development of biopsy needles and several catheter products is progressing while maintaining the 5 activity areas and focus areas. - FY2021-Q3RestatedAnnual report
「Group-wide R&D spending for the nine months ended the third quarter was ¥238.371 million. There were no material changes in the status of the Group's R&D activities during the nine months ended the third quarter.」
The company recorded R&D expenses of ¥238.371 million for the nine months ended the third quarter and stated that there were no material changes in the status of its R&D activities. - FY2021-Q2RestatedAnnual report
「Group-wide R&D spending for the six months ended the second quarter was ¥148.912 million. There were no material changes in the status of the Group's R&D activities during the six months ended the second quarter.」
The company recorded R&D expenses of ¥148.912 million for the six months ended the second quarter and stated that there were no material changes in the status of its R&D activities. - FY2021-Q1RestatedAnnual report
「The Group's total R&D expenditure for the first quarter cumulative period was ¥73.335 million. There were no material changes in the status of the Group's R&D activities during the first quarter cumulative period.」
R&D expenses for the first quarter cumulative period were ¥73.335 million, and the company stated that there were no material changes in its R&D activities. - FY2020Reducing the R&D structure and expenditure while specifying development activitiesAnnual report
「Accordingly, we divide R&D responsibilities covering information gathering and product commercialization from basic research through applied research, with activities conducted by 5 departments and 38 staff. The activities comprise ① gathering information on customer needs, ② improving existing products, ③ proposals from medical institutions concerning safety measures used in medical settings, ④ proposals from medical institutions concerning contributions to patients' QOL (Quality of Life), and ⑤ expanding applications of catheter technology. In particular, we are focusing on R&D for needle products with mechanisms to prevent needlestick accidents, proposed by medical institutions as a safety measure used in medical settings, and intravascular treatment catheter products related to interventional procedures (angio) and IVR. As a result of these initiatives, R&D expenses for the consolidated fiscal year were ¥218.544 million, equivalent to 1.1% of net sales.」
While maintaining its 5 R&D areas and priority fields, the company reduced staff from 41 to 38 and R&D expenses from ¥242.920 million in the previous fiscal year to ¥218.544 million. - FY2020-Q3RestatedAnnual report
「The Group's total R&D expenditure for the third quarter cumulative period was ¥152.994 million. There were no material changes in the status of the Group's R&D activities during the third quarter cumulative period.」
The company recorded R&D expenses of ¥152.994 million for the third quarter cumulative period and stated that there were no material changes in its R&D activities. - FY2020-Q2RestatedAnnual report
「The Group's total R&D expenditure for the second quarter cumulative period was ¥101.928 million. There were no material changes in the status of the Group's R&D activities during the second quarter cumulative period.」
The company recorded R&D expenses of ¥101.928 million for the second quarter cumulative period and stated that there were no material changes in its R&D activities. - FY2020-Q1RestatedAnnual report
「The Group's total R&D expenditure for the first quarter cumulative period was ¥51.140 million. There were no material changes in the status of the Group's R&D activities during the first quarter cumulative period.」
The company recorded first-quarter R&D expenses of ¥51.140 million and stated that there were no material changes in its R&D activities. - FY2019-Q3RestatedAnnual report
「The Group's total R&D expenditure for the third quarter cumulative period was ¥175.712 million. There were no material changes in the status of the Group's R&D activities during the third quarter cumulative period.」
The company recorded R&D expenses of ¥175.712 million for the third quarter cumulative period and stated that there were no material changes in its R&D activities. - FY2019-Q2RestatedAnnual report
「The Group's total R&D expenditure for the second quarter cumulative period was ¥111.454 million. There were no material changes in the status of the Group's R&D activities during the second quarter cumulative period.」
The company recorded R&D expenses of ¥111.454 million for the second quarter cumulative period and stated that there were no material changes in its R&D activities. - FY2019-Q1RestatedAnnual report
「The Group's total R&D expenditure for the first quarter cumulative period was ¥57.415 million. There were no material changes in the status of the Group's R&D activities during the first quarter cumulative period.」
The company recorded first-quarter R&D expenses of ¥57.415 million and stated that there were no material changes in its R&D activities. - FY2018RestatedAnnual report
「Accordingly, we divide R&D responsibilities covering information gathering and product commercialization from basic research through applied research, with activities conducted by 5 departments and 41 staff. The activities comprise ① gathering information on customer needs, ② improving existing products, ③ proposals from medical institutions concerning safety measures used in medical settings, ④ proposals from medical institutions concerning contributions to patients' QOL (Quality of Life), and ⑤ expanding applications of catheter technology. In particular, we are focusing on R&D for needle products with mechanisms to prevent needlestick accidents, proposed by medical institutions as a safety measure used in medical settings, and intravascular treatment catheter products related to angio and IVR. As a result of these initiatives, R&D expenses for the consolidated fiscal year were ¥242.920 million, equivalent to 1.4% of net sales.」
The company maintained its 5-department, 41-person structure and its focus on safety-mechanism needle products and intravascular treatment catheters, recording R&D expenses of ¥242.920 million for the period. - FY2018-Q3RestatedAnnual report
「The Group's total R&D expenditure for the third quarter cumulative period was ¥171.572 million. There were no material changes in the status of the Group's R&D activities during the third quarter cumulative period.」
The company recorded R&D expenses of ¥171.572 million and stated that there were no material changes in its R&D activities. - FY2018-Q2RestatedAnnual report
「The Group's total R&D expenditure for the second quarter cumulative period was ¥114.691 million. There were no material changes in the status of the Group's R&D activities during the second quarter cumulative period.」
The company recorded R&D expenses of ¥114.691 million for the second quarter cumulative period and stated that there were no material changes in its R&D activities. - FY2018-Q1RestatedAnnual report
「The Group's total R&D expenditure for the first quarter cumulative period was ¥54.413 million. There were no material changes in the status of the Group's R&D activities during the first quarter cumulative period.」
The company recorded first-quarter R&D expenses of ¥54.413 million and stated that there were no material changes in its R&D activities. - FY2017RestatedAnnual report
「Amid major changes in the operating environment, the Group's basic policy is to conduct R&D on products that meet diverse, increasingly sophisticated customer needs across a broad range of areas and to pursue value creation. Accordingly, we divide R&D responsibilities covering information gathering and product commercialization from basic research through applied research, with activities conducted by 5 departments and 41 staff. The activities comprise ① gathering information on customer needs, ② improving existing products, ③ proposals from medical institutions concerning safety measures used in medical settings, ④ proposals from medical institutions concerning contributions to patients' QOL (Quality of Life), and ⑤ expanding applications of catheter technology. In particular, we are focusing on R&D for needle products with mechanisms to prevent needlestick accidents, proposed by medical institutions as a safety measure used in medical settings, and intravascular treatment catheter products related to angio and IVR. As a result of these initiatives, R&D expenses for the consolidated fiscal year were ¥237.238 million, equivalent to 1.4% of net sales.」
The company maintained its 5 R&D areas and 41-person structure and its focus on safety-mechanism needle products and intravascular treatment catheters, recording annual R&D expenses of ¥237.238 million. - FY2017-Q3SoftenedAnnual report
「The Group's total R&D expenditure for the third quarter cumulative period was ¥175.444 million. The changes in R&D activities during the third quarter cumulative period were as follows. On 6 December 2016, the company and Anges MG, Inc. agreed to terminate their joint development agreement for an NF-κB decoy oligodeoxynucleotide-coated PTA balloon catheter.」
While reporting total R&D expenditure, the company disclosed the termination of the joint development agreement for the drug-coated PTA balloon catheter, which had been a priority area, indicating that the scope of its R&D initiatives had narrowed in part. - FY2017-Q2RestatedAnnual report
「The Group's total R&D expenditure for the second quarter cumulative period was ¥116.563 million. There were no material changes in the status of the Group's R&D activities during the second quarter cumulative period.」
The company recorded ¥116.563 million in R&D expenditure and stated that there were no material changes in its R&D activities. - FY2017-Q1RestatedAnnual report
「The Group's total R&D expenditure for the first quarter cumulative period was ¥59.518 million. There were no material changes in the status of the Group's R&D activities during the first quarter cumulative period.」
The company recorded ¥59.518 million in R&D expenditure and stated that there were no material changes in its R&D activities. - FY2016First statedAnnual report
「Accordingly, we divide R&D responsibilities covering information gathering and product commercialization from basic research through applied research, with activities conducted by 5 departments and 41 staff. The activities comprise ① gathering information on customer needs, ② improving existing products, ③ proposals from medical institutions concerning safety measures used in medical settings, ④ proposals from medical institutions concerning contributions to patients' QOL (Quality of Life), and ⑤ expanding applications of catheter technology. In particular, we are focusing on R&D for needle products with mechanisms to prevent needlestick accidents, proposed by medical institutions as a safety measure used in medical settings, and intravascular treatment catheter products related to angio and IVR.」
For R&D in fiscal 2015, the company specifies a structure of 5 departments and 41 staff, 5 areas of activity and priority product fields.